Background and Purpose-Cerebral microbleeds (CMBs) predispose patients to intracerebral hemorrhage. Preclinical models to examine the effects of antithrombotic treatments on the development of clinically overt intracerebral hemorrhage are needed. We examined the natural course of CMB development and the effects of long-term anticoagulation with warfarin or dabigatran on cerebral micro-and macrohemorrhage in mice overexpressing the APP23 (amyloid precursor protein). Methods-Repeated susceptibility-weighted magnetic resonance imaging was performed in APP23 mice at the age of 18 and 21 months, respectively. After establishing stable long-term anticoagulation effects of warfarin and dabigatran on number and total volume of CMBs, the outcome parameters were compared with nonanticoagulated control. Results-CMBs were equally located in lobar and deep brain regions, and number and total volume of CMBs increased over time. Anticoagulation with either warfarin or dabigatran did not increase CMBs in APP23 significantly. Mice treated with warfarin numerically had a higher mortality (nonanticoagulated: 31%; dabigatran: 35% versus warfarin: 55%; P=0.21).
C erebral microangiopathies are an important cause of ischemic brain infarction and dementia in the elderly. 1, 2 Certain microangiopathies also increase the risk of intracerebral hemorrhage (ICH). Magnetic resonance imaging (MRI) allows identifying small foci of blood extravasation in the brain of healthy subjects and patients with stroke, which are referred to as cerebral microbleeds (CMBs). 3 Albeit oversimplified, the topographical distribution of CMBs reflects the underlying cerebral microangiopathy. Deep CMBs are associated with hypertensive arteriopathy, whereas lobar CMBs are related to cerebral amyloid angiopathy. 4, 5 Mounting evidence suggests that CMBs are an important risk marker of subsequent clinically overt ICH. This has vast epidemiological implications in aging populations worldwide as >30% of octogenarians have at least 1 and 10% even have multiple CMBs. 6 At the same time, many elderly patients have an indication for long-term antithrombotic medication. Oral anticoagulation (OAC) with vitamin K antagonists or direct oral anticoagulants (DOACs) is the therapy of choice for stroke prevention in atrial fibrillation, a condition with a population prevalence of 10% in octogenarians. 7 Notably, ICH is the most feared complication of OAC. 8 The potential link between CMBs and an increased risk of ICH has led to concerns about the safety of antithrombotic therapy in patients with CMBs. 9 In cerebral microangiopathies, deposition of extracellular material disintegrates vessel wall texture and damages smooth muscle cells resulting in microvascular occlusion or leakage.
cerebral microangiopathies in general and CMBs in particular is the limited availability of suitable animal models. There is evidence of extracellular blood in transgenic mouse models of amyloid-associated Alzheimer disease 11 and spontaneously hypertensive rats. 12, 13 A preclinical model would be important to evaluate the effects of new antithrombotic medications for translation into the clinic.
Our study aimed to characterize the natural history of CMBs in aged transgenic APP23 mice using repetitive susceptibility-weighted imaging (SWI). Specifically, we evaluated the effects of long-term anticoagulation with warfarin or the DOAC dabigatran on cerebral micro-and macrohemorrhage.
Materials and Methods
Eighty-one heterozygous APP23 transgenic mice (line kindly supplied by Matthias Jucker, Tübingen, Germany; n=38 male, n=43 female) were used for MRI experiments. At baseline, 18-to 19-month-old mice were included based on pilot MRI data showing no CMBs in 15-month-old APP23 mice. Animals dying during an MRI session were excluded from the study (n=2).
Additional young (12-20 weeks old; n=21) and aged (>18 months; n=15) wild-type (C57B16 background backcrossed with APP23) animals were used to establish the efficacy of long-term anticoagulation with dabigatran etexilate (DE, mouse chow provided by Boehringer Ingelheim) and warfarin (Coumadin; Bristol-Myers-Squibb), respectively. All animals were treated in accordance with international and institutional guidelines for animal welfare after approval by the governmental authority (Regierungspräsidium Karlsruhe).
Experimental Protocol
Mice were randomly assigned to receive no anticoagulation (control, n=26), warfarin in drinking water (n=29), or DE in mice chow (n=26). Animals underwent baseline SWI to detect CMBs. A subsequent MRI scan was performed 3 to 4 months after the first scan. Some of the animals (n=31) underwent scanning at additional time points (1 and 2 months). After the 3-to 4-month MR examination, mice were culled and brains were collected for subsequent examination.
Long-Term OAC With Warfarin and DE
To determine effects of warfarin and DE, respectively, in mice prone to develop CMBs, protocols for long-term OAC in mice were newly established. The dose for anticoagulation with warfarin was established in 17 young wild-type mice based on previous experience with short-term anticoagulation.
14 Four concentrations of warfarin dissolved in drinking water were evaluated: 3.1, 3.125, 3.25, and 3.5 mg/L. The degree of anticoagulation was tested once a week for 6 weeks after initiation of warfarin using a point-of-care coagulometer (PoC; Coaguchek XS, Roche, Germany) to measure the international normalized ratio (INR). PoC INR values in the range of 2.2 to 4.0 were considered effective anticoagulation based on previous calibration INR measurements performed in the central laboratory of University Hospital Heidelberg (Innovin clotting assay, CA-7000; Siemens Healthcare Diagnostics).
14 Anticoagulation with DE was induced in young wild-type mice (n=4) using a diet consisting of DE-loaded chow (10 mg DE/g chow).
The success of anticoagulation was tested 7 days after initiation of feeding with DE chow using a diluted thrombin time assay 15 (onlineonly Data Supplement). To ascertain that anticoagulation with warfarin and DE had a similar anticoagulant effect, we measured in vivo tail vein bleeding time in 15 aged mice (5 warfarin, 5 DE, and 5 control) 16 (online-only Data Supplement).
Magnetic Resonance Imaging
Imaging was performed on a 9.4 T Bruker BioSpec 94/20 USR small animal system (Bruker, Germany) equipped with 740 mT/m gradients and a 1H surface cryogenic probe and interfaced to ParaVision 6.0.1 software. To visualize CMBs, a strongly T2-weighted 2D FLASH technique was performed. 17 SWI contrast was achieved with a built-in routine that uses the complex phase information of the acquired data (online-only Data Supplement).
Data Analysis
MR data analysis was performed on SW images by a rater blinded to group assignment using ImageJ software (National Institutes of Health, Bethesda, MD). The outcome parameters were spatial distribution, number, and volume of CMBs (online-only Data Supplement).
Correspondence of MRI Findings With Postmortem Iron Deposition
To confirm correspondence of hypointense foci on SW images with CMBs, Prussian blue staining was performed in 5 APP23 mice (online-only Data Supplement).
Postmortem Analysis in Prematurely Dying APP23
Animal care staff was instructed to freeze corpses of prematurely dying mice whenever possible for postmortem dissection. Brains were harvested, sectioned coronally into six 1-mm-thick slices, and scanned at 300 dpi. Brain bleeding (macrobleeds) was manually delineated and measured using ImageJ. Hematoma volume was determined by multiplying measured areas with slice thickness.
Statistical Analysis
Analysis was performed using GraphPad Prism 7.3 (GraphPad Software, San Diego, CA). Bar graphs are presented as mean±SD. Student t test was used for comparison between 2 groups. For multiple-group comparison, ANOVA with post hoc Tukey test was used after validating for the normal distribution by Kolmogorov-Smirnov test. 
Location and Natural History of Microbleeds in APP23 Mice
Forty-six APP23 mice underwent the MRI protocol comprising baseline MRI and subsequent 3-to 4-month scanning. SWI revealed that 57% of APP23 mice had at least 1 CMB at baseline and 95% of mice had at least 1 CMB at 3 to 4 months. The spatial distribution of foci of hypointense signal in APP23 mice at baseline showed 48% of CMBs in cortical structures of the brain and the remainder in the striatum. At 3 to 4 months after baseline imaging, 44% of CMBs were located in cortex and the remainder in the striatum ( Figure 1B) . Number of CMBs and total CMB volume increased significantly in APP23 mice during the 3-month period between scans (Student's t test, P=0.004 and P=0.009, respectively; Figure 1B and 1C) .
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Sex Differences
Nonanticoagulated female APP23 mice had a significant increase in number and volume of CMBs at 3-to 4-month follow-up compared with baseline ( Figure 2A and 2B, ANOVA with Tukey post hoc test, P=0.0001 and P=0.0005, respectively). Furthermore, a significantly larger number and volume of CMBs was found in female compared with male APP23 mice at 3 to 4 months ( Figure 2A and 2B, ANOVA with Tukey post hoc test, P=0.0021 and P=0.0015, respectively). Long-term anticoagulation with the chow containing DE (n=4) resulted in a dabigatran plasma concentration of 704±316 ng/mL. Anticoagulation with the chow also substantially prolonged tail vein bleeding time exceeding the maximum recording time of 15 minutes in all animals (ANOVA with Tukey post hoc, P<0.0001).
Establishment of Long-Term Anticoagulation

Effect of Oral Anticoagulants on CMBs in APP23 Mice
Long-term anticoagulation with either warfarin or DE did not increase significantly the number and the total volume of CMBs compared with nonanticoagulated control on follow-up MR scans ( Figure 4A and 4B) . A sex comparison of the effect of anticoagulation with either warfarin or dabigatran on the number and volume of CMBs showed no statistical difference (online-only Data Supplement).
Postmortem Analysis of Prematurely Dying APP23 Mice
Thirty-three APP23 animals died prematurely during the follow-up period. Numerically, mortality was higher in the warfarin group than in the control and the dabigatran groups but this did not reach statistical significance (31% control, 35% dabigatran, 55% warfarin, Mantel-Cox test, P=0.21; Figure 5A ). Of the 33 prematurely dying mice, 22 brains could be recovered for postmortem dissection (control: 8/8, dabigatran: 5/9, Figure 5C ). In contrast, 5 brains from dying mice treated with warfarin had large intracerebral bleedings on postmortem analysis ( Figure 5C ). A significant increase in the risk of large bleedings in prematurely dying APP23 mice treated with warfarin compared with the control and the dabigatran group, respectively, was found ( Figure 5C , ANOVA with Tukey post hoc test, P=0.01 and P=0.03, respectively).
Retrospective analysis of early follow-up scans from the 5 mice with large macrobleeds revealed a CMB in the area of the subsequent macrobleed in the preceding MRIs in all animals ( Figure 5D ).
Discussion
Preclinical models allowing the investigation of the biology underlying CMBs and the effects of antithrombotics in the development of macroscopic ICH have not been established. The major new findings of our study are that (1) female APP23 mice have earlier and more progressive development of CMBs, (2) based on newly established protocols for longterm anticoagulation with warfarin, warfarin and DE do not promote the formation of CMBs in APP23 mice compared with nonanticoagulated mice, (3) despite similar intensity of systemic anticoagulation, warfarin but not dabigatran induces large macroscopic ICH in APP23 mice.
CMBs were found in deep and cortical locations in APP23 mice in our study. This spatial distribution is consistent with previous studies reporting foci of low-signal intensity on SWI in cortical and thalamic brain regions of aged APP23 mice. 11, 13 This corresponds to the deposition of amyloid both in deep and cortical brain microvessels in APP23 mice. 11, 18 The subsequent development of CMBs was progressive in APP23 mice >3 to 4 months. This progression of CMBs is corroborated by postmortem observations by Winkler et al 11 in 19-and 27-month-old APP23 mice. Our observations in APP23 mice partially correspond to neuroimaging and postmortem findings in healthy elderly human subjects and patients with cerebral amyloid angiopathy in whom CMBs are predominantly lobar. 5, 19, 20 In contrast, deep-seated CMBs are associated with chronic hypertensive microangiopathy. 3, 4 A study using the same APP23 mouse line found similar kinetics of CMB manifestation in males compared with females. 11 In our study, CMBs were higher in female than in male APP23 mice at baseline and particularly at follow-up. A potential explanation for sex-dependent progression of CMBs is that female APP23 mice produce more amyloid β40 and 42 and show more robust amyloid pathology in the brain. 18 An important goal was to test the effect of long-term anticoagulation on CMBs and macroscopic ICH. An obstacle was that long-term anticoagulation with warfarin had not been established in mice. The pharmacokinetics and pharmacodynamics of vitamin K antagonists differ substantially between rodents and humans including a much shorter anticoagulation effect in mice. 21, 22 Based on published short-term anticoagulation protocols with warfarin, 23, 24 we established an effective warfarin dose that produces anticoagulation as evidenced by 
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in vitro and in vivo coagulation testing. We compared the effects of warfarin to a DOAC by anticoagulation of animals with a chow containing dabigatran. This resulted peak dabigatran plasma levels of 704.14 ng/mL and prolonged systemic bleeding time similar to warfarin. It is an unresolved issue whether anticoagulation promotes the formation of CMBs in humans. In most but not all crosssectional studies, previous anticoagulation with vitamin K antagonists was associated with more CMBs and the proportion of patients with >5 CMBs was higher in anticoagulated subjects. 25 However, this may be confounded by the higher age of anticoagulated subjects. A clinically more relevant question is whether anticoagulation increases the risk of symptomatic ICH in the presence of CMBs. 26 This question is awaiting prospective evidence from observational studies such as CROMIS-II (Clinical Relevance of Microbleeds in Stroke) and HERO (Intracerebral Hemorrhage due to Oral Anticoagulants) 27 and from neuroimaging substudies of clinical trials in embolic stroke of undetermined source. 28 In our study, anticoagulation with warfarin or dabigatran did not increase the number of CMBs in APP23 mice.
Intriguingly, warfarin caused large ICH in at least 17% of warfarin-treated APP23 mice. Some of these hemorrhages are likely to have contributed to the numerically higher mortality in APP23 mice treated with warfarin. In contrast, anticoagulation with dabigatran did not cause large ICH and did not affect mortality compared with nonanticoagulated control mice. This discrepancy corresponds to a consistently 50% lower rate of ICH in patients on DOACs than in patients on warfarin. 29 The biology underlying this discrepancy between warfarin and DOACs and the pronounced differences on ICH reduction as compared with systemic bleeding are not well understood at present. Potential mechanisms include the preservation of normal factor VII (factor VII) activity in patients anticoagulated with DOACs, whereas vitamin K antagonists reduce FVII activity. Interaction of tissue factor with activated FVIIa is a particularly important hemostatic step after brain damage. Alternative immediate effects of the different anticoagulants on vascular pathology in the case of cerebral amyloid angiopathy remain to be explored. Tissuetype plasminogen activator in APP23 mice leads to an increase in CAA-associated microhemorrhages and can provoke parenchymal and subarachnoidal hematomas. 30 Furthermore, experimental studies have shown that nicotine increases focal ischemic brain injury. 31 Therefore, smoking and vascular risk factors, including CAA, may increase the risk of ICH in patients undergoing treatment with oral anticoagulants. Bleeding risk may be reduced if thrombolytic drugs are given with cytoprotectants and vasoprotectants such as recombinant APC (activated protein C). 32, 33 The promotion of cytoprotective signaling targeting the injured vessel wall and brain cells using APC or similar approaches is a promising area of ongoing experimental 32, 33 and clinical research 34, 35 with potential for prevention of bleeding in both hyperacute stroke therapies such as thrombolysis and as an adjuvant for long-term anticoagulation in subjects with cerebral small-vessel disease.
Beyond gaining insights into the biology of this specific anticoagulation conundrum, APP23 may be a useful tool to evaluate the safety of new antithrombotic drugs preclinically in the future.
Strengths and Limitations
APP23 mice are not a pure model of cerebral amyloid angiopathy as they show generalized parenchymal rather than isolated vascular amyloid deposition. On the contrary, vascular amyloid deposition is recognized as an important component of Alzheimer pathology. 36 The terminology used for characterization of CMBs on SWI in humans differs from the operational definition used in our study that refers to CMBs as any area of hypointense signal with the diameter of at least 1 pixel (ie, diameter of 55 µm) without setting an upper threshold. Moreover, CMB volume as measured by SWI does not represent the true volume of affected tissue as the MR signal has high sensitivity to field inhomogeneity caused by blood resulting in a blooming effect. Another limitation is that the pharmacokinetics of warfarin and dabigatran differ substantially between mouse and man. We made anticoagulants continuously available in food or water to compensate for shorter half-lives in mice. Producing comparable anticoagulation efficacy using different antithrombotic drugs in an animal model has limitations as appropriate in vitro coagulation tests differ among drugs. Therefore, we performed in vivo testing of tail vein bleeding time to compare systemic anticoagulation effects. Blood pressure measurements were not performed on APP23 mice in our study, but previous observations of coauthors found normal blood pressure using invasive BP measurements in anesthetized mice. Histopathological analysis of amyloid deposition was not performed in our study. Winkler et al 11 showed that APP23 mice have progressive smooth muscle cells loss and an increasing amyloid burden in the vessel wall between age 19 and 27 months. Finally, the present exploratory study was not powered to detect a difference in mortality among different groups. Potential effects on mortality need to be confirmed in adequately powered studies.
In conclusion, aged APP23 mice progressively develop CMBs. Mirroring aspects of the clinical scenario, warfarin but not dabigatran promotes the formation of extensive brain bleeding. Thus, APP23 may be useful to study aspects of the pathophysiology of cerebral microangiopathy predisposing to bleeding and for preclinical safety evaluation of antithrombotic therapies in elderly subjects. 
